| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30070040 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070041 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070042 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070043 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070044 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070045 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070046 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070047 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070048 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
| TVIS30070049 | HIV | ENSG00000184428.13 | protein_coding | TOP1MT | No | No | 116447 | Q969P6 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TOP1MT |
|---|---|
| DrugBank ID | DB00762 |
| Drug Name | Irinotecan |
| Target ID | BE0000091 |
| UniProt ID | Q969P6 |
| Regulation Type | inhibitor |
| PubMed IDs | 17139284; 17016423; 15170677; 15255290; 15975002; 16309825; 16454746; 11752352; 19852077; 9342501 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, Suzuki T, Togawa T, Yoshida H, Soda H, Oka M, Kohno S, Sawada S, Ishikawa T, Tanabe S: Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer. 2004 Jul 20;110(6):921-7.@@Yoshikawa M, Ikegami Y, Sano K, Yoshida H, Mitomo H, Sawada S, Ishikawa T: Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid. J Exp Ther Oncol. 2004 Apr;4(1):25-35.@@Yang X, Hu Z, Chan SY, Chan E, Goh BC, Duan W, Zhou S: Novel agents that potentially inhibit irinotecan-induced diarrhea. Curr Med Chem. 2005;12(11):1343-58.@@Nakagawa H, Saito H, Ikegami Y, Aida-Hyugaji S, Sawada S, Ishikawa T: Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett. 2006 Mar 8;234(1):81-9. Epub 2005 Nov 23.@@Ishikawa T, Ikegami Y, Sano K, Nakagawa H, Sawada S: Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells. Curr Pharm Des. 2006;12(3):313-25.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23. doi: 10.1002/bmc.1345.@@Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet. 1997 Oct;33(4):245-59. |
| Groups | Approved; Investigational |
| Direct Classification | Camptothecins |
| SMILES | CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12 |
| Pathways | Irinotecan Action Pathway; Irinotecan Metabolism Pathway |
| PharmGKB | PA450085 |
| ChEMBL | CHEMBL481 |
